Bottle Label 20mg (43353 857)
This is a product description for Tadalafil (Cialis) which consists of 12 tablets containing 20mg of the active ingredient.*
Cialis
Product Images NDC 43353-857
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Cialis (NDC 43353-857). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aphena Pharma Solutions (TN)
Chemical Structure (Cialis Uspi F001 Structure V1)
Figure (Cialis Uspi F001 V2)
This is a graph representing the concentration levels of Tadalafil in plasma at different time intervals after administration of a single 20-mg dose of Tadalafil, a single 5-mg dose of Tadalafil, and once-daily 5-mg Tadalafil following 5 consecutive days of administration. The concentration levels are measured in μg/L and the time intervals are indicated in hours.*
Figure (Cialis Uspi F002 V1)
This appears to be a table that shows the difference in blood pressure (measured in mmHg) between taking Tadalafil (a medication used for erectile dysfunction) and a placebo. The table also includes measurements for standing and supine systolic and diastolic blood pressure at different time intervals.*
Figure (Cialis Uspi F003 V1)
This appears to be a figure or chart with some numbers and characters, possibly related to a medical study involving different medications and dosages over time. Without additional context or associated labels, it is not possible to provide a more specific description.*
Figure (Cialis Uspi F004 V1)
The text provided is a table containing information about the effect of a combination of medications on systolic blood pressure at different times. The medications used are 20 mg tadalafil and 8 mg qd doxazosin, and there is also a placebo group. The table shows four different groups based on the medication and time after administration. Therefore, this text provides data from a scientific experiment that evaluates the impact of these medications on the systolic blood pressure.*
Figure 5 (Cialis Uspi F005 V1)
This is a graph or chart showing the change in IPSS (International Prostate Symptom Score) total score over the duration of treatment. The chart shows two groups, one treated with medication (CIAUSSmg) and the other with placebo. The scored values range from 2 to 6. The graph indicates that the medication group had a significantly lower IPSS score than the placebo group. The duration of treatment ranges from 4 to 12 weeks.*
Figure 6 (Cialis Uspi F006 V1)
The text describes a graph or a chart that shows the change from Baseline in IPSS Total Score for two different treatments over a certain duration of treatment in weeks. One treatment is represented by "CIALIS 5mg" and the other by "Placebo". There is a statistically significant difference between the two treatments as denoted by the asterisk and the text "*p<0.01".*
Figure 7 (Cialis Uspi F007 V2)
Figure 8 (Cialis Uspi F008 V1)
The text shows the change from baseline in IPSS total score with the use of Ciaus 5mg and Placebo after 12 weeks of treatment, where the asterisk represents statistical significance.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
